Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers?

Future Oncology

Volumn 11, Issue 22, 2015, Pages 3053-3055

  Kourie, Hampig Raphael ^a   Awada, Ahmad Hussein ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

checkpoint inhibitors; immunotherapy; metachronous cancer; synchronous cancer

Indexed keywords

IPILIMUMAB;

ADVANCED CANCER; CANCER IMMUNOTHERAPY; CANCER REGISTRY; CANCER THERAPY; CARCINOGENESIS; CLINICAL PRACTICE; HEALTH CARE QUALITY; HUMAN; MULTIPLE CANCER; PRIORITY JOURNAL; REVIEW; CANCER STAGING; DISEASE MANAGEMENT; IMMUNOTHERAPY; MOLECULARLY TARGETED THERAPY; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; PATHOLOGY; PROCEDURES;

DISEASE MANAGEMENT; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; STANDARD OF CARE;

EID: 84946849455     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.15.187     Document Type: Review

References (16)

1. Spratt J, Hoag M. Incidence of multiple primary cancers per man-year of follow up: 20-year review from the Ellis Fischel State Cancer Hospital. Ann. Surg. 164, 775-784 (1996).
2. Curtis R, Freedman D, Ron E et al. New malignancies among cancer survivors: SEER cancer registries, 1973-2000. NIH Publ. No. 05-5302. Bethesda, MD, USA: National Cancer Institute (2006). http://seer. cancer. gov
3. Luciani A, Balducci L. Multiple primary malignancies. Semin. Oncol. 31, 264-273 (2004).
4. Hayat MJ, Howlader N, Reichman ME et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12, 20-37 (2007).
5. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271, 907-913 (1994).
6. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J. Clin. Oncol. 14, 7-17 (1996).
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12, 252-264 (2012).
8. Garrett MD, Collins I. Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol. Sci. 32, 308-316 (2011).
9. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
10. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134-144, (2013).
11. Weber JS, D'Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol. 16, 375-384 (2015).
12. Rizvi NA, Mazières J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a Phase 2, single-arm trial. Lancet Oncol. 16, 257-265 (2015).
13. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versusgemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825 (2011).
14. Kourie HR, Markoutsaki N, Roussel H et al. Double pancreatic and gastric adenocarcinomas: a rare association. Clin. Res. Hepatol. Gastroenterol. 37, e137-e140 (2013).
15. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72(5), 1117-1130 (2003).
16. Oza AM, Cibula D, Benzaquen AO et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised Phase 2 trial. Lancet Oncol. 16(1), 87-97 (2015).